OptiBiotix Health PLC Presentation of research data

TIDMOPTI

OptiBiotix Health PLC

24 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Presentation of research at Microbiome R&D and Business Collaboration: Asia

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it will be presenting research data on its microbiome modulators at the Microbiome R&D and Business Collaboration Congress: Asia, in Hong Kong on the 1-2 March 2017. The conference brings together experts in all areas of microbiome research and is recognised around the world as one of theleading conferences for bringing together pharma, biotech, academic institutions and investors who are looking to develop and progress ground-breaking microbiome research into next generation products through partnering.

OptiBiotix's conference abstract and presentation covers research which demonstrates the company's ability to create designer ingredients which can modify an individual's microbiome. These studies suggest commercial potential for:-

i. The development of species or genera specific prebiotics which can selectively enhance the growth and health benefits of existing probiotic products. This new product concept, called an OptiBiotic(R), has the potential to enhance probiotic health benefits and provide product differentiation in the probiotic market, a market forecast to be worth more than $46.5bn by 2020 (Markets and Markets).

ii. Designer ingredients which can modify an individual's current microbiome to improve health. These ingredients are heat resistant and stable during processing, which creates the opportunity to incorporate low cost, safe, ingredients which modulate specific elements of the microbiome in a wide range of food products.

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "The ability to create designer ingredients which can modify an individual's microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development. I believe we are fast approaching the next stage in the development of the microbiome in healthcare, where scientists have the ability to precision engineer components of the microbiome to prevent, manage and treat many of today's chronic lifestyle diseases."

For further information, please contact:

 
 OptiBiotix Health plc                 www.optibiotix.com 
 Stephen O'Hara, Chief Executive     Contact via Walbrook 
                                      below 
 
 Walbrook PR Ltd                   Tel: [phone] or [e-mail] 
 Anna Dunphy                           Mob: [phone] 
                                        001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABRGDBIGDBGRX

(END) Dow Jones Newswires

January 24, 2017 02:01 ET (07:01 GMT)